Home Featured Page 103

Featured

Latest

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Reunion Neuroscience Schedules Fiscal Third Quarter 2023 Conference Call for Tuesday,...

Mindset Pharma Receives Another Allowance from USPTO for Patent Application Expanding...

The Agenda for Economic Analyses of Psychedelic-assisted Therapy

A Perspective on Providers: Scaling PAT in a Time of Therapist...

Making “Access” A Meaningful Part of Every Conversation about Psychedelic Therapy

Psychedelic Therapies: From Approvals to Access

PharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program...

Small Pharma Announces Update on Intellectual Property Portfolio with Two New...

Numinus Receives Clinical Trial Application Approval from Health Canada for Experiential...

PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to...

1...102103104...291 Page 103 of 291

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

Dylan Beynon – Mindbloom – At Home Ketamine

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Reunion Neuroscience Schedules Fiscal Third Quarter 2023 Conference Call for Tuesday,...

Mindset Pharma Receives Another Allowance from USPTO for Patent Application Expanding...

The Agenda for Economic Analyses of Psychedelic-assisted Therapy

A Perspective on Providers: Scaling PAT in a Time of Therapist...

Making “Access” A Meaningful Part of Every Conversation about Psychedelic Therapy

Psychedelic Therapies: From Approvals to Access

PharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program...

Small Pharma Announces Update on Intellectual Property Portfolio with Two New...

Numinus Receives Clinical Trial Application Approval from Health Canada for Experiential...

PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to...

EDITOR PICKS

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

Dylan Beynon – Mindbloom – At Home Ketamine

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY